Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

Ivana Gojo, MD, Alison Walker, MD, Maureen Cooper, MD, Eric J Feldman, MD, Swaminathan Padmanabhan, MBBS, MS, Maria R Baer, MD, Jennifer Poon, PharmD, Karen Small, BSN, Da Zhang, MS, Mariola Sadowska, PhD, Rajat Bannerji, MD, PhD

Blood (2010) 116 (21): 3287.

https://doi.org/10.1182/blood.V116.21.3287.3287

Published: 2010

Journal Articles

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Larry D. Cripe, Michael Maris, MD, Maureen Cooper, MD, Shaker R. Dakhil, MD, Richard M Stone, MD, Francesco Turturro, MD, Tianling Chen, MD, MSc, Kristi Mahadocon, Judith Fox, Craig Berman, Glenn C Michelson, MD, Robert K Stuart

Blood (2009) 114 (22): 1037.

https://doi.org/10.1182/blood.V114.22.1037.1037

Published: 2009

Journal Articles

A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Stage II, III or IV Chronic Lymphocytic Leukemia (CLL).

Raul R. Mena, MD, Mehdi M. Moezi, MD, Robert L. Robles, MD, Maureen Cooper, MD

Blood (2007) 110 (11): 1356.

https://doi.org/10.1182/blood.V110.11.1356.1356

Published: 2007

Journal Articles

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD

Blood (2006) 108 (11): 2712.

https://doi.org/10.1182/blood.V108.11.2712.2712

Published: 2006

Journal Articles

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Francis Giles, MD, Susan O’Brien, MD, David Rizzieri, MD, Judith Karp, MD, Maureen Cooper, MD, Ghulam Mufti, MD, Bonny Johnson, MSN, Verena Karsten, PhD, Norbert Vey, MD

Blood (2005) 106 (11): 2786.

https://doi.org/10.1182/blood.V106.11.2786.2786

Published: 2005

Journal Articles

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Madeleine Duvic, MD, Debra Breneman, MD, Maureen Cooper, MD, Gustavo Fonseca, MD, J. Claude Bennett, MD, J. Michael Kilpatrick, PhD, Shanta Bantia, PhD

Blood (2005) 106 (11): 2683.

https://doi.org/10.1182/blood.V106.11.2683.2683

Published: 2005

NARROW

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Stage II, III or IV Chronic Lymphocytic Leukemia (CLL).

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Email alerts

ASH Publications

American Society of Hematology

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Stage II, III or IV Chronic Lymphocytic Leukemia (CLL).

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

Phase I/II Study of Oral Fodosine TM , a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only